TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02621112

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intradermal HBVv with imiquimod
Description: Intradermal hepatitis B vaccine with imiquimod pretreatment

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intradermal HBVv with aqueous cream
Description: Intradermal hepatitis B vaccine with aqueous cream pretreatment

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular HBVv with aqueous cream
Description: Intramuscular hepatitis B vaccine with aqueous cream pretreatment
Study: NCT04228588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 MG [Nucala]
Description: Mepolizumab 100mg, SC, every 4 weeks
Study: NCT03714724

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Intraabdominal Pressure Measurement
Description: In this method, a sterile set system (AbViser- Wolfe Tory Medical, Saik Lake City, Utah, USA) was used in normal conditions. Measurements will be made in 20 ml saline was given, Pressure transducer was used as a reset point pubic symphysis and intra-abdominal pressure was measured.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Intraabdominal Pressure Measurement
Description: In this method, a sterile set system (AbViser- Wolfe Tory Medical, Saik Lake City, Utah, USA) was used in normal conditions. Measurements will be made in 20 ml saline was given, Pressure transducer was used as a reset point pubic symphysis and intra-abdominal pressure was measured.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Intraabdominal Pressure Measurement
Description: In this method, a sterile set system (AbViser- Wolfe Tory Medical, Saik Lake City, Utah, USA) was used in normal conditions. Measurements will be made in 20 ml saline was given, Pressure transducer was used as a reset point pubic symphysis and intra-abdominal pressure was measured.
Study: NCT01657175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive care
Description: The patients will be randomized to control or supportive care groups.~The control group will be given care as usual wich include clinical follow-ups at the surgical department.~The supportive care group get in addition to the clinical follow-ups a supportive care programme including:~* Discharge information about surgery and life after surgery together with their relatives.~* Active telephone contacts 1/week th first month the 2/month up to six month after discharge by a specialized nurs.~* Open telephone line were the patients can call the nursed ruing daytime. Discharge: approximately 2-4 weeks after surgery
Study: NCT00580736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Clearing
Description: Optical Clearing
Study: NCT00354679

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study: NCT00705679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir 1% vaginal gel
Description: 1 gm/100 ml of 1% gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir placebo
Description: placebo gel
Study: NCT01571401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trying Activity for Kidney Cancer Survivors (TRACKS) Trial
Description: Participants in both arms will be provided with six individual supervised exercise sessions with a physical activity specialist that will taper to an unsupervised program by the end of the intervention. Over the 4-week period, both groups will be required to attend two sessions per week for weeks 1-2, and one session per week for weeks 3-4 at the Behavioural Medicine Fitness Centre at the University of Alberta. In order to achieve the PA guidelines established by the current public health recommendations, additional unsupervised sessions will be prescribed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trying Activity for Kidney Cancer Survivors (TRACKS) Trial
Description: Participants in both arms will be provided with six individual supervised exercise sessions with a physical activity specialist that will taper to an unsupervised program by the end of the intervention. Over the 4-week period, both groups will be required to attend two sessions per week for weeks 1-2, and one session per week for weeks 3-4 at the Behavioural Medicine Fitness Centre at the University of Alberta. In order to achieve the PA guidelines established by the current public health recommendations, additional unsupervised sessions will be prescribed.
Study: NCT00354679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: proteomic profiling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT04775771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal Assisted Practice
Description: The children, who were planned to be hospitalized for at least three days and were randomized to the experimental and control groups, were asked by the researcher using the face-to-face interview technique, and the questions in the patient information form were filled in on the form. Then, pre-test data were recorded by determining their anxiety levels with the State Anxiety Scale for Children, levels of fear with the Child Fear Scale, emotional and psychological well-being with the Stirling Children's Emotional and Psychological Well-being Scale. Unlike the other scales, the anxiety levels were assessed twice with one-hour intervals on the first day with the Children's State Anxiety Scale. On the third day, the anxiety levels were evaluated twice with one-hour intervals on the first day using the State Anxiety Scale for Children. The second group, the children in the control group, had the same procedure except for the intervention; but no intervention was made.
Study: NCT04338087

Intervention type: OTHER
Intervention: Questionnaire and personal interviews.
Description: Questionnaire and personal interviews.

Intervention type: OTHER
Intervention: Questionnaire and personal interviews.
Description: Questionnaire and personal interviews.
Study: NCT03121508

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Taking on Diabetes to Advance You (TODAY) Project
Description: This is an individualized educational intervention with activity components designed to assist in modifying habits, roles, and routines to promote healthy lifestyle patterns for individuals with type 2 diabetes.
Study: NCT01837784

Intervention type: OTHER
Intervention: Optimization of blood pressure according to guidelines
Description: There is no specific recommendation for the intervention. The goal of the intervention is an optimization of blood pressure control. The intervention is at the discretion of the physician, but should adhere to guidelines. The intervention may therefore embrace measures such as drug prescriptions or lifestyle interventions.

Intervention type: OTHER
Intervention: Optimization of blood pressure according to guidelines
Description: There is no specific recommendation for the intervention. The goal of the intervention is an optimization of blood pressure control. The intervention is at the discretion of the physician, but should adhere to guidelines. The intervention may therefore embrace measures such as drug prescriptions or lifestyle interventions.

Intervention type: OTHER
Intervention: Optimization of blood pressure according to guidelines
Description: There is no specific recommendation for the intervention. The goal of the intervention is an optimization of blood pressure control. The intervention is at the discretion of the physician, but should adhere to guidelines. The intervention may therefore embrace measures such as drug prescriptions or lifestyle interventions.
Study: NCT01576289

Intervention type: OTHER
Intervention: Histological analysis
Description: Systematic histological analysis of biopsy specimens obtained during routine endoscopic examination
Study: NCT03706443

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systane Complete
Description: Lubricant eye drop which is based on propylene glycol 0.6%. Used for temporary relief of burning and irritation due to dryness of the eye.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systane Ultra
Description: Lubricant eye drop which is based on polyethylene glycol 400 0.4% and propylene glycol 0.3%. Used for temporary relief of burning and irritation due to dryness of the eye.
Study: NCT01095432

Intervention type: PROCEDURE
Intervention: PWS Testing
Description: Partial wave spectroscopy (PWS)has been developed to allow scientists to learn about any changes to the cells that may indicate a risk of developing colon cancer.
Study: NCT04513548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ligelizumab
Description: One injection every four weeks
Study: NCT01837784

Intervention type: OTHER
Intervention: Optimization of blood pressure according to guidelines
Description: There is no specific recommendation for the intervention. The goal of the intervention is an optimization of blood pressure control. The intervention is at the discretion of the physician, but should adhere to guidelines. The intervention may therefore embrace measures such as drug prescriptions or lifestyle interventions.
Study: NCT04513548

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One injection every four weeks
Study: NCT02596438

Intervention type: OTHER
Intervention: Hepatitis B
Description: Hepatitis B Surface Antigen, Hepatitis B Surface Antibody and Hepatitis B Core AB, Total Testing
Study: NCT02716818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronocort®
Description: Chronocort® is a patented oral modified release formulation of hydrocortisone which is intended to mimic, or closely match, the serum levels of endogenous cortisol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard glucocorticoid therapy
Description: Subjects in this arm will continue on their standard hydrocortisone therapy
Study: NCT04314804

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PPP001
Description: 1 pellet smoked up to 3 times a day with titanium pipe (280 mg dried cannabis pellet - 9% THC / 2% CBD per pellet)

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pellet smoked up to 3 times a day with titanium pipe (280 mg dried cannabis pellet - 0% THC / 0.6% CBD per pellet)
Study: NCT00139074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine fumarate
Description: oral variable dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate
Description: oral variable dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium valproate
Description: oral
Study: NCT01156220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Injection, 40 mg, single dose over 5 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Injection, 40 mg, single dose over 5 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminohippurate sodium
Description: Injection, 500 mg, single dose over 5 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminohippurate sodium
Description: Injection, 500 mg, single dose over 5 min
Study: NCT02459119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib will be packaged as 40 mg tablets in a bottle. Patients will be instructed to maintain a daily medication calendar.
Study: NCT02181309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam, medium dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam, high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam, high dose
Study: NCT04487912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tilmanocept
Description: Combined peri-areolar and peri-tumoral injection of 99m-Tc Tilmanocept

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nanocolloid
Description: Combined peri-areolar and peri-tumoral injection of 99m-Tc Nanocolloid
Study: NCT04729413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples Counseling
Description: Psychoeducational counseling on relationships and maternal and child health in the context of HIV.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Enhanced Standard of Care
Description: Enhanced standard of care with education on pregnancy and postpartum health, similar to what is presented to women at routine antenatal and postpartum care.
Study: NCT01119105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC-3781
Description: BC-3781 dose 100mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC-3781
Description: BC-3781 dose 150mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
Study: NCT05080816

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral nutrition (PN)
Description: Overnight infusion of parenteral nutrition. Supplied as all-in-one-bag format. Infusion rate of 0.2 g N/kg/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enteral nutrition
Description: Oral nutrition drink. 2 \* 200 ml on the night before operation. 1\* 200 ml on the morning of operation day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Overnight infusion of crystalloid fluid (Ringer acetate) infused at the same rate (ml/kg) as intervention PN
Study: NCT02055781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy
Study: NCT01413776

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Corn Soya Blend+
Description: A blended food consisting of corn (75-80%) and soybeans (20-25%) that has been fortified with a premix of 19 vitamins and minerals.
Study: NCT00892073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide
Description: Diazoxide will be initiated at half the dose (100 mg per day) for 2 weeks to allow the insulin sensitizing action of metformin to take effect. Dosage will be increased to 200mg daily, divided twice daily with meals for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be initiated at 500 mg twice daily and increased to 1000 mg twice daily over a one week period to minimize gastrointestinal side effects. the 2000mg is to be taken with meals for 6 months.
Study: NCT02272088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity-moderate
Description: cross -over of moderate and intense physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity-moderate
Description: cross -over of moderate and intense physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intense physical activity
Description: cross -over of moderate and intense physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intense physical activity
Description: cross -over of moderate and intense physical activity
Study: NCT01678105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Treatment continued until Disease Progression, Toxicity, or patient withdrawal
Study: NCT00431080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 as an IV infusion over 1h every two weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2 as an IV infusion over 3hrs every two weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluoruracil
Description: 5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluoruracil
Description: 5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating growth factor
Description: rhG-CSF 5 μg/kg/d on days 3-10 after each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating growth factor
Description: rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
Study: NCT01035073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 30-60 mg daily for 8 weeks
Study: NCT03318042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: The group consumed a daily serving of walnuts (30 g) or 200 mL pomegranate juice for 3 days and provided a sample of urine as well as a swab specimen from the inner cheek

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pomegranate juice
Description: Those volunteers who were allergic to nuts consumed 200 mL pomegranate juice daily for 3 days and provided a sample of urine as well as a swab specimen from the inner cheek
Study: NCT05631470

Intervention type: DIAGNOSTIC_TEST
Intervention: MR screening
Description: This study is to compare the results of MR-FFR with pressure-wired-based FFR measurement.
Study: NCT02415452

Intervention type: PROCEDURE
Intervention: drug-eluting stent implantation
Description: The DES contains Firebird , sirolimus-eluting stents, paclitaxel-eluting stents , or zotarolimus-eluting stents . Unfractionated heparin was used during percutaneous coronary intervention .A loading dose of 300 mg clopidogrel was given to all patients prior to PCI, followed by a maintenance dose of 75 mg daily for 12 months before it was stopped.
Study: NCT05443152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fetal movement and position tracking training
Description: In the first stage, pregnant women were trained to implement fetal movement count and position tracking. The training was provided face to face and lasted 30-45 minutes. How to determine the position of the fetus and I. and II. Leopold maneuvers are also taught. In the second stage, the pregnant women were interviewed twice a week by telephone.Thus, it was provided that pregnant women had fetal tracked at least once a day, at any time of the day, when the fetus was awake and most active, in a suitable position and a comfortable environment, for at least 15-20 minutes continuously for four weeks. Pregnant women phoned the researcher when they wanted. At the same time, the participants continued to their routine prenatal care.
Study: NCT02093559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief counseling Intervention
Description: The brief counseling intervention will utilize MI and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address HIV risk behaviors and determine readiness for change in substance use.
Study: NCT01423032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: 100 mg/m² iv, day 1+2, q4w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: 25 mg/m² iv, days 1-5, q4w
Study: NCT02977637

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Feraheme MRI/MRA
Study: NCT00522873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)
Description: One capsule \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 13 cycles (28 days per cycle).
Study: NCT05223270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wound dressing under the NIMV mask
Description: wound dressing under the NIMV mask

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wound dressing under the NIMV mask
Description: wound dressing under the NIMV mask
Study: NCT03369418

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-Stim Active
Description: The study device is a safe, commercially available take-home cranial electrotherapy stimulation device that applies an electrical current to a subject's head to treat anxiety, depression or insomnia

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Alpha-Stim Inactive
Description: The study device given to the inactive group will be identical to the active except the electrodes attached to the device will be inactive. The device will not transmit anything when turned on because the electrodes are inactive.
Study: NCT03586713

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: light induced fluorescence camera
Description: The light induced fluorescence intraoral camera works with a visible blue light frequency (wavelength 450 nm) for the illumination of the dental surface and produces an overlapping image of the green fluorescence image on the image of the white light. The green fluorescence image is considered an indicator of healthy dental tissues. The colour of the fluorescence signal is green when the dentin is healthy. The healthy enamel is blue due to the scattered green light of the dentin, despite the lack of a fluorescence signal. On the other hand, caries can be easily detected by dark red fluorescence.
Study: NCT03947619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impella CP® placement prior to reperfusion with Primary PCI
Description: Subjects randomized to the experimental arm, will undergo Impella CP® placement through a femoral arterial sheath and the Impella device will be activated to unload the left ventricle.